دورية أكاديمية
The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy.
| العنوان: | The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy. |
|---|---|
| المؤلفون: | Portoles JM; Department of Nephrology, Hospital Universitario Puerta de Hierro, Madrid, Spain.; Research net REDInREN 016/0009, Instituto Salud Carlos III, Madrid, Spain., Jimenez C; Research net REDInREN 016/0009, Instituto Salud Carlos III, Madrid, Spain.; Department of Nephrology, Hospital La Paz, Madrid, Spain., Janeiro D; Department of Nephrology, Hospital Universitario Puerta de Hierro, Madrid, Spain.; Research net REDInREN 016/0009, Instituto Salud Carlos III, Madrid, Spain., Lopez-Oliva MO; Research net REDInREN 016/0009, Instituto Salud Carlos III, Madrid, Spain.; Department of Nephrology, Hospital La Paz, Madrid, Spain., Ortega-Carrion A; R+D Department, BIOHOPE Scientific SL, Madrid, Spain., Blanquez D; Adamas Engineering Consulting, Madrid, Spain., Arribas L; Adamas Engineering Consulting, Madrid, Spain., Gomez C; R+D Department, BIOHOPE Scientific SL, Madrid, Spain., Diez T; R+D Department, BIOHOPE Scientific SL, Madrid, Spain., Pascual J; Research net REDInREN 016/0009, Instituto Salud Carlos III, Madrid, Spain.; Department of Nephrology, Hospital del Mar, Institut Mar for Medical Research, Barcelona, Spain., Portero I; R+D Department, BIOHOPE Scientific SL, Madrid, Spain. |
| المصدر: | Frontiers in immunology [Front Immunol] 2021 Jan 25; Vol. 11, pp. 618202. Date of Electronic Publication: 2021 Jan 25 (Print Publication: 2020). |
| نوع المنشور: | Journal Article; Observational Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Drug Resistance*, Immunologic Tests/*methods , Immunosuppressive Agents/*therapeutic use , Leukocytes, Mononuclear/*drug effects, Aged ; Female ; Graft Rejection/immunology ; Graft Rejection/prevention & control ; Humans ; In Vitro Techniques ; Kidney Transplantation ; Leukocytes, Mononuclear/immunology ; Male ; Middle Aged |
| مستخلص: | Immunosuppressive drugs are widely used to treat several autoimmune disorders and prevent rejection after organ transplantation. However, intra-individual variations in the pharmacological response to immunosuppressive therapy critically influence its efficacy, often resulting in poor treatment responses and serious side effects. Effective diagnostic tools that help clinicians to tailor immunosuppressive therapy to the needs and immunological profile of the individual patient thus constitute a major unmet clinical need. In vitro assays that measure immune cell responses to immunosuppressive drugs constitute a promising approach to individualized immunosuppressive therapy. Here, we present the Immunobiogram, a functional pharmacodynamic immune cell-based assay for simultaneous quantitative measurement of a patient's immune response to a battery of immunosuppressive drugs. Peripheral blood mononuclear cells collected from patients are immunologically stimulated to induce activation and proliferation and embedded in a hydrogel mixture in which they are exposed to a concentration gradient of the immunosuppressants of interest. Analysis of samples from kidney transplant patients using this procedure revealed an association between the sensitivity of individual patients to the immunosuppressive regimen and their immunological risk of transplant rejection. Incorporation of the Immunobiogram assay into clinical settings could greatly facilitate personalized optimization and monitoring of immunosuppressive therapy, and study of the mechanisms underlying resistance to immunosuppressants. Competing Interests: This research involved the use of proprietary technologies belonging to BIOHOPE and covered by European Patent: EP 17 382 399.8 “METHOD FOR PREDICTING AND MONITORING CLINICAL RESPONSE TO IMMUNOMODULATORY THERAPY”. Inventors (current or former employees at Biohope): Javier Dotor de las Herrerias, Marianna di Scala, Veronica Sanchez, Isabel Portero Sanchez. AO, TD, and IP are employees at Biohope. LA and BD were employed by Adamas Engineering Consulting. The authors declare that this study was sponsored by Biohope. Biohope was beneficiary of a full funding from a competitive grant from the European Commission to conduct the study, and coordinated the study and the assignation of the adjudicated (and by EU audited) funding to the entities (research institutions, CRO and statistical company) that took part in the study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Portoles, Jimenez, Janeiro, Lopez-Oliva, Ortega-Carrion, Blanquez, Arribas, Gomez, Diez, Pascual and Portero.) |
| التعليقات: | Expression of concern in: Front Immunol. 2023 Aug 15;14:1272763. (PMID: 37720235) |
| References: | Am J Transplant. 2011 Oct;11(10):2093-109. (PMID: 21883901) Int J Pharm. 2004 May 4;275(1-2):259-69. (PMID: 15081156) Cell Transplant. 2009;18(5):639-46. (PMID: 19775526) J Cell Sci. 2012 Jul 1;125(Pt 13):3015-24. (PMID: 22797912) Front Immunol. 2019 Dec 19;10:2978. (PMID: 31921213) J Vis Exp. 2015 Jun 12;(100):e52948. (PMID: 26131645) Clin Pharmacol Ther. 1998 Apr;63(4):465-70. (PMID: 9585801) Clin Lab Med. 2019 Dec;39(4):643-656. (PMID: 31668275) Transpl Int. 2005 Feb;18(2):140-50. (PMID: 15691265) Clin Pharmacokinet. 2012 Nov;51(11):711-41. (PMID: 23018468) Clin Pharmacol Ther. 2009 Sep;86(3):285-9. (PMID: 19404248) Transplant Rev (Orlando). 2019 Oct;33(4):191-199. (PMID: 31377099) Eur J Immunol. 2016 Dec;46(12):2695-2704. (PMID: 27861809) Cell Med. 2014 Dec 12;7(2):51-7. (PMID: 26858893) Int Immunopharmacol. 2007 Jan;7(1):3-22. (PMID: 17161812) PLoS One. 2011 May 10;6(5):e19680. (PMID: 21572959) Transplantation. 1988 Dec;46(6):853-7. (PMID: 2974655) Russ J Immunol. 2002 Dec;7(4):335-42. (PMID: 12687245) Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Dec;26(6):1765-1771. (PMID: 30501718) Arch Toxicol. 2014 Jul;88(7):1351-89. (PMID: 24792322) Clin J Am Soc Nephrol. 2016 Feb 5;11(2):332-43. (PMID: 26170177) Adv Biochem Eng Biotechnol. 2007;106:41-73. (PMID: 17680228) J Nephrol. 2019 Dec;32(6):851-870. (PMID: 30927190) J Immunother. 2004 Sep-Oct;27(5):405-18. (PMID: 15314550) Mol Biol Cell. 2015 Feb 15;26(4):685-95. (PMID: 25518938) Curr Drug Metab. 2018;19(6):513-522. (PMID: 29380698) Biol Pharm Bull. 2016;39(7):1085-90. (PMID: 27374283) J Clin Pharmacol. 2005 Jul;45(7):751-62. (PMID: 15951465) Am J Transplant. 2014 Oct;14(10):2317-27. (PMID: 25146383) PLoS One. 2015 Dec 30;10(12):e0146021. (PMID: 26717316) Clin Ther. 2014 Aug 1;36(8):1264-72. (PMID: 25037282) J Allergy Clin Immunol. 1992 Mar;89(3):714-21. (PMID: 1545093) Infect Dis Clin North Am. 2019 Dec;33(4):1143-1157. (PMID: 31668195) Am J Transplant. 2009 Nov;9 Suppl 3:S1-155. (PMID: 19845597) Transplant Proc. 2005 Jul-Aug;37(6):2823-5. (PMID: 16182820) Expert Opin Drug Saf. 2016;15(3):303-19. (PMID: 26667069) APL Bioeng. 2018 Mar 29;2(2):021501. (PMID: 31069295) Expert Opin Drug Saf. 2019 Apr;18(4):285-294. (PMID: 30909754) Endocr Dev. 2013;24:41-56. (PMID: 23392094) Int J Clin Pharmacol Ther. 2011 Feb;49(2):145-52. (PMID: 21255531) Expert Opin Investig Drugs. 2006 Mar;15(3):267-91. (PMID: 16503764) J Immunoassay Immunochem. 2006;27(2):195-205. (PMID: 16711256) Am Rev Respir Dis. 1991 Nov;144(5):1016-25. (PMID: 1952426) |
| فهرسة مساهمة: | Keywords: cellular pharmacodynamics; immune cell assay; immunosuppressive therapy monitoring; personalized medicine; transplant rejection |
| المشرفين على المادة: | 0 (Immunosuppressive Agents) |
| تواريخ الأحداث: | Date Created: 20210211 Date Completed: 20210621 Latest Revision: 20230918 |
| رمز التحديث: | 20230918 |
| مُعرف محوري في PubMed: | PMC7868528 |
| DOI: | 10.3389/fimmu.2020.618202 |
| PMID: | 33569062 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2020.618202 |